Theralink Technologies Inc (THER)

[BooDog]

OncBioMune Pharmaceuticals, Inc. OTCQB






Common Stock SEC Reporting - Current

OTCQB






0.05720.0103 (15.26%)


Real-Time Best Bid & Ask
0.0571 / 0.064 (10000 x 49957)


Previous Close

0.0675

Open

0.0689


Daily Range

0.0572 - 0.069

52wk Range

0.05 - 0.42


Volume

417,123

Dividend

N/A


Average Vol (30d)

196,967

Getting closer to Phase 2 kick off for proscaVax at the Beth Israel Deaconess Medical Center/Harvard Medical School, the host hospital network for the study.

In the trial, ProscaVax, OncBioMune’s novel immunotherapeutic cancer vaccine consisting of a combination of tumor-associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF), will be evaluated for safety, tolerability and efficacy in treatment-naïve prostate cancer patients at disease presentation. Per the protocol, patients to be enrolled in the study will be newly diagnosed with prostate cancer, deciding in collaboration with their oncologist to forego standard approved therapies, such as a radical prostatectomy, radiation or brachytherapy, in favor of careful monitoring for disease progression, a process known more commonly as “active surveillance.” Presently, there are no FDA-approved treatments for prostate cancer patients in active surveillance.